Skip to content
Review

Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.

Nov 2026 · European Journal of Pharmacology · pp. 179530 · 0 citations · 83 references
Medicine

Abstract

The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long history of clinical use in China, prevents SARS-CoV-2 infection by downregulating the viral entry receptor ACE2 through inhibition of HIF-1α and JAK2/STAT3 signaling. This review synthesizes the pleiotropic pharmacological mechanisms of daphnetin, including anti-inflammatory (NF-κB, JAK/STAT, NLRP3), antioxidant (Nrf2/Keap1), immunomodulatory (Th17/Treg balance), and mitochondrial protective pathways. These pathways are critically involved in the pathogenesis of both severe COVID-19 and rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We propose that daphnetin represents a novel "one agent, dual protection" strategy: it not only blocks viral entry by reducing ACE2 but also mitigates the hyperinflammatory and oxidative stress states that exacerbate both COVID-19 severity and rheumatic disease activity. Given its established safety, oral activity, and low cost, daphnetin is a promising candidate for clinical translation in high-risk comorbid populations. Key unresolved questions and future research directions are also discussed.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.